Bridge Programs and Free-Drug Programs for IBD Biologics

When coverage for an inflammatory bowel disease biologic stalls, the clock keeps running on your dosing schedule. Prior authorization reviews, plan-year restarts, formulary changes, and job transitions all create windows where a prescription is written but nobody will pay for it. Manufacturers and nonprofit foundations run programs designed for exactly that window. A bridge program for biologic medication supplies drug at no cost while a coverage decision is pending, and a free-drug program, usually called a patient assistance program, supplies drug on an ongoing basis to people who have no coverage or cannot afford what their plan leaves behind. Knowing which category you need, and having the paperwork ready before you call, is what separates a two-week interruption from a two-month one.

Why coverage gaps in IBD are common and consequential

Delays are the norm rather than the exception. A study of 190 pediatric IBD patients found that prior authorization added a median of 10.2 days to biologic initiation, and 24.6 days when appeals or step therapy were involved, with roughly one preventable adverse outcome for every eight patients who required authorization. In adults, an analysis of 66 patients reported an average approval time of 30.5 days, ranging as high as 145 days, with longer waits among patients on public insurance. Even dose escalation for someone already on therapy is not immune: when appeals were required, median time from the decision to escalate to insurance approval was 29 days. A survey of 2,017 IBD patients found that 72% had encountered at least one insurer-mandated barrier and 22% had experienced a gap in therapy because of insurance, with medication denials associated with higher odds of IBD-related surgery.

What an interruption does to biologic therapy

Biologics work on fixed intervals. Vedolizumab maintenance is 300 mg intravenously every eight weeks after the induction doses, and ustekinumab maintenance is 90 mg subcutaneously every eight weeks. Missing a dose is a pharmacologic event, not only an administrative one. Loss of response to anti-tumor necrosis factor therapy affects up to 50% of patients over time and is frequently driven by low drug concentrations and anti-drug antibodies, and low trough levels during a gap are one route to antibody formation. The infliximab label states that readministration after a period of no treatment produced a higher incidence of infusion reactions than regular maintenance dosing, with serious infusion reactions in 4% of retreated psoriasis patients versus under 1% on continuous maintenance. Since medications for Crohn's disease work by bringing on and maintaining remission rather than curing the disease, continuity matters.

Bridge programs versus free-drug programs

Bridge programs are manufacturer-run and time-limited. They exist to cover the interval between a prescription and a payer decision, and they typically require that a claim has been submitted and is pending, denied, or under appeal. Takeda's START program for vedolizumab, for example, advertises product at no cost with no enrollment delay for eligible patients, covering both the intravenous formulation and the pen, and is accessed through EntyvioConnect. Free-drug patient assistance programs are means-tested and open-ended. Takeda's Help At Hand program describes itself as a needs-based program providing free medicine to eligible patients who have no insurance or not enough insurance. Most manufacturers of IBD biologics operate one of each, and the intake phone line is usually shared, so ask specifically which program you are being enrolled in and for how long. Directories such as NeedyMeds index these programs by drug name.

The eligibility information checklist

Assistance program intake staff ask for the same categories of information across nearly every manufacturer, and having them assembled shortens the call considerably. Gather the following before you begin.

• Household size, prior-year adjusted gross income, and proof such as a tax return, recent pay stubs, or a Social Security benefits letter
• Insurance details including plan name, member and group numbers, pharmacy benefit manager, and copies of any denial letter or explanation of benefits
• Prescriber information including the prescribing physician's name, NPI number, fax number, and the specific drug, dose, and frequency prescribed

Programs also commonly ask for citizenship or lawful residency status, a diagnosis code, and a signed authorization allowing the manufacturer to speak with your insurer and prescriber. Enrollment forms almost always require both a patient signature and a prescriber signature, which is where applications most often stall.

Why federal beneficiaries face different rules

Manufacturer copay cards and bridge cards are generally unavailable to anyone enrolled in Medicare, Medicaid, TRICARE, or the Veterans Health Administration. The reason is the federal Anti-Kickback Statute, which makes it a crime to knowingly offer remuneration to induce the purchase of any item for which payment may be made under a federal health care program. The Office of Inspector General notes that remuneration includes anything of value, not only cash. Free-drug patient assistance programs are structured differently and often do accept federal beneficiaries, so a Medicare enrollee turned down for a copay card should still ask about the manufacturer's free-drug arm and about independent charitable foundations. The HealthWell Foundation operates disease-specific funds that cover coinsurance, copayments, deductibles, and premiums, though individual funds open and close as money is replenished.

Coordinating assistance with your appeal

Assistance programs buy time, and appeals resolve the underlying problem, so run both at once. Under federal rules your insurer must decide a prior authorization request within 15 days, within 30 days for services already received, and within 72 hours for urgent care cases, and you have 180 days from a denial notice to file an internal appeal. If the internal appeal fails, you can request an external review by an independent third party whose decision the plan must honor, and urgent cases can be filed concurrently with the internal appeal. Watch how your plan treats any assistance dollars you receive, because federal regulation permits but does not require plans to count direct support offered by drug manufacturers toward the annual limitation on cost sharing, which is the mechanism behind copay accumulator programs.

Most bridge enrollments carry an expiration date, most free-drug enrollments require annual recertification with updated income documentation, and most foundation grants run for a defined benefit period. Each one has a renewal date that arrives without a reminder from anyone. Writing down the program name, the enrollment date, the expiration date, and a direct phone number for each application you file is the single practical step that keeps a temporary solution from becoming a second gap.